Komori

Eisai Co.,Ltd.

4523PharmaceuticalsLarge cap
4,937JPY+1.7%
★ Watch (sign-up required)
Price history
¥4,937Latest-28.2%
Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis
Business overview

The Group operates primarily in pharmaceuticals. For FY2025, revenue was ¥825.4 billion, operating income was ¥44.1 billion, net income was ¥40.5 billion (net income attributable to owners of the parent was ¥38.6 billion), and core operating income was ¥50.1 billion. Key products include Lenvima, Leqembi and Dayvigo. The Group is advancing development in combination therapies and global health. Its five reportable segments cover Japan, North America, China, EMEA and Asia, among others. Under its medium-term business plan, EWAY Future & Beyond, the Group aims to develop and commercialize innovative medicines in dementia, oncology and global health while creating social value.

Recurring subjects
No threads yetThis company's filings have not been read yet. We are adding them progressively.
Companies sharing a theme
Loading
Documents
See all timely disclosuresSee all statutory filings
News
See all news
Key numbersShowing 8 of 20
PER
74.42How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.
PBR
1.45How many times the company's net assets? Around 1x is generally considered a benchmark.
ROE
2.0%Earning power. A figure above 10% is generally considered good.
Dividend yield
0.0%The annual dividend as a percentage of the share price.
Market capitalization
¥1.4tnShare price × number of shares. The value of the entire company.
Equity ratio
58.2%The proportion of assets funded by money that does not have to be repaid.
Operating margin
10.6%The percentage of revenue remaining from the company’s core business.
Revenue growth (3 years)
6.0%The average annual growth in sales over the past three years.
What to watch next
Expansion of Leqembi (lecanemab) indications and updates to coverage conditions, including continued expansion of US coverage and developments in the European review process
Impact HighLikelihood Medium
Expansion of Leqembi administration formats, including further regulatory progress toward subcutaneous maintenance dosing and the adoption of IQLIK
Impact MediumLikelihood Medium
Progress in the clinical evidence for AHEAD 3-45, which targets asymptomatic AD, including confirmation that the study is moving from the implementation phase to the results phase
Impact HighLikelihood Low
Progress in integrating the dementia ecosystem, including whether a collaboration and monetisation model for エコナビスタ becomes visible
Impact MediumLikelihood Medium
Improving external assessments of key development and priority projects, such as continued regulatory progress for E2814, including Fast Track designation
Impact MediumLikelihood Medium
What to watch next
Loading
Who owns itTop holders total 33.9%
Listed holders 33.9%Everyone else 66.2%
The Master Trust Bank of Japan, Ltd. (Trust Account)18.55%
株式会社日本カストディ銀行 (Trust Account)9.99%
STATE STREET BANK AND TRUST COMPANY 5050015.31%
Who owns it
HolderOwnership (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)18.55
株式会社日本カストディ銀行 (Trust Account)9.99
STATE STREET BANK AND TRUST COMPANY 5050015.31
This company's documents
Filings
Timely disclosures
Threads